Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. There is growing evidence for the involvement of glutamatergic abnormalities in schizophrenia. Uncompetitive NMDA receptor (NMDAR) antagonists induce effects closely resembling both the positive and negative symptoms of schizophrenia candidate risk genes for schizophrenia converge on the NMDAR expressing synapse